To the full analysis
Insulet stock: growth
PODDInsulet reported $2.71B in revenue for fiscal 2025, up 30.7% on the prior year, up 24.5% a year on average over up to five years.
Daily figure as of 12 Nov 2026
Revenue (Annual rate)
41.6%
per year from 2006 to 2025, per share 12.7%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 24.5% | 26.2% | 41.6% |
| Revenue per share | 22.5% | 23.5% | 12.7% |
| Earnings | 105.2% | no data | no data |
| Earnings per share | 99.9% | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $3.66M | −$35.95M | −$44.96M |
| 2007 | $13.37M | −$53.54M | −$60.46M |
| 2008 | $36.06M | −$92.79M | −$92.66M |
| 2009 | $66.03M | −$79.54M | −$52.46M |
| 2010 | $96.97M | −$61.16M | −$42.17M |
| 2011 | $152.26M | −$57.17M | −$36.57M |
| 2012 | $211.37M | −$51.87M | −$40.05M |
| 2013 | $247.08M | −$44.97M | −$3.96M |
| 2014 | $288.72M | −$51.5M | −$2.57M |
| 2015 | $263.89M | −$73.52M | −$23.16M |
| 2016 | $366.99M | −$28.88M | −$6.2M |
| 2017 | $463.77M | −$26.83M | −$36.02M |
| 2018 | $563.82M | $3.29M | −$126.46M |
| 2019 | $738.2M | $11.6M | −$72.5M |
| 2020 | $904.4M | $6.8M | −$82.5M |
| 2021 | $1.1B | $16.8M | −$190.8M |
| 2022 | $1.31B | $4.6M | −$38.3M |
| 2023 | $1.7B | $206.3M | $70.1M |
| 2024 | $2.07B | $418.3M | $305.4M |
| 2025 | $2.71B | $247.1M | $377.7M |
Revenue by segment
How Insulet Corp. makes its money and how that has shifted. Names are as the company reports them.
- International Omnipod99%
- Drug Delivery1%
Figures as a table
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|---|---|
| International Omnipod | $673.5M | $834.9M | $1.01B | $1.25B | $1.66B | $2.03B | $2.67B | 98.7% |
| Drug Delivery | $64.7M | $69.5M | $87.4M | $57.5M | $36M | $38.9M | $34.1M | 1.3% |
| Total revenue | $738.2M | $904.4M | $1.1B | $1.31B | $1.7B | $2.07B | $2.71B | 100% |
Revenue by region
Where Insulet Corp. generates its revenue.
- United States72%
- Outside the US28%
Figures as a table
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $295.1M | $343.82M | $391.8M | $485.1M | $596.4M | $738.9M | $942.3M | $1.29B | $1.55B | $1.95B | 72.2% |
| Outside the US | $71.89M | $119.95M | $172.02M | $253.1M | $308M | $359.9M | $363M | $410.1M | $523.4M | $754.3M | 27.9% |
| Total revenue | $366.99M | $463.77M | $563.82M | $738.2M | $904.4M | $1.1B | $1.31B | $1.7B | $2.07B | $2.71B | 100% |
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 19 Sep 2025)
- Valuation signal Undervalued since 7 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.